Multiple Myeloma | Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting — Multiple Myeloma (Part 3)
Free with Audible trial. Cancel anytime.
Quick Facts
| Author | Unknown |
| Narrator | Unknown |
| Runtime | 0h58m |
| Published | April 19, 2021 |
| Rating | 4.5 / 5 (19 ratings) |
| Categories | Health & Wellness, Physical Illness & Disease, Hygiene & Healthy Living, Science & Engineering, Science |
| Format | Audiobook (Digital) |
| Platform | Audible |
Featured Audiobooks
Handpicked listeners' favorites this week
About This Audiobook
Proceedings from part 3 of a 4-part webinar series. Featuring perspectives from Drs Robert Z Orlowski, S Vincent Rajkumar and Edward A Stadtmauer, ...
Why Listen to Multiple Myeloma | Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting — Multiple Myeloma (Part 3)?
- Expert narration by Unknown brings every character and scene to life across 0h58m of immersive audio.
- Bestseller-quality story from Unknown, rated 4.5 stars by 19 listeners.
- Free with your Audible trial — keep the audiobook forever even if you cancel.
- Perfect for commutes, workouts, and relaxation. Listen anywhere, anytime.
Download: Multiple Myeloma | Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting — Multiple Myeloma (Part 3)
Some links on this page are affiliate links. If you make a purchase through one of them, we may earn a small commission at no extra cost to you.
Multiple Myeloma | Recent Advances in Hematologic Oncology: A 4-Part Live Webinar Series Reviewing Key Data and Presentations from the 62nd ASH Annual Meeting — Multiple Myeloma (Part 3) by Unknown is an immersive listening experience. Performed by Unknown with a runtime of 0h58m, you can start with a free trial that you can cancel at any time. The audiobook remains yours forever, even if you end the trial.